Literature DB >> 17118999

Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis.

José A Riancho1, Carmen Valero, Angel Naranjo, Dieter J Morales, Carolina Sañudo, María T Zarrabeitia.   

Abstract

CONTEXT: Osteoporosis has a significant genetic component. The aromatase-dependent conversion of androgenic precursors is the main source of estrogens in postmenopausal women.
OBJECTIVE: The objective of the investigation was to study the relationship of a set of single nucleotide polymorphisms (SNPs) of the aromatase gene with osteoporosis and determine their functional influence on gene transcription. DESIGN, PARTICIPANTS, AND METHODS: This was a case-control study including 135 women with vertebral fractures due to postmenopausal osteoporosis and 312 controls. Alleles at four SNPs situated between exons I.2 and 3 were determined by Taqman assays. Total aromatase RNA and differential allelic-specific expression were studied by RT-real time PCR in adipose tissue samples taken from 50 individuals.
RESULTS: The SNPs studied were in strong linkage disequilibrium. A common haplotype, present in about half of the population, was identified as being associated with an increased risk of fractures (odds ratio 1.8, 95% confidence interval 1.2-2.8, P = 0.006). There was evidence of differential allelic expression. In heterozygous individuals, transcripts bearing T alleles at rs700518 SNP (which were included in the risk haplotype) were less abundant than those with the alternative C alleles (P < 0.001). Total aromatase expression was four times lower in fat samples from individuals who were homozygotes for the unfavorable alleles than in the opposite homozygotes (P = 0.007).
CONCLUSIONS: A common haplotype of aromatase associated with gene expression is also associated with the risk of osteoporotic vertebral fractures in postmenopausal women. These data are in line with the hypothesis that the aromatase-dependent synthesis of estrogens plays an important role in bone homeostasis in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118999     DOI: 10.1210/jc.2006-1616

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.

Authors:  Gurusamy Umamaheswaran; Steven Aibor Dkhar; Sekar Kalaivani; Raj Anjana; Mohan Revathy; Mohammad Jaharamma; Kulumani Mahadevan Lakshmi Shree; Dharanipragada Kadambari; Chandrasekaran Adithan
Journal:  Med Oncol       Date:  2013-07-28       Impact factor: 3.064

2.  Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.

Authors:  Nicola Napoli; Antonella Rastelli; Cynthia Ma; Georgia Colleluori; Swapna Vattikuti; Reina Armamento-Villareal
Journal:  Pharmacogenet Genomics       Date:  2015-08       Impact factor: 2.089

3.  HTR1B, ADIPOR1, PPARGC1A, and CYP19A1 and obesity in a cohort of Caucasians and African Americans: an evaluation of gene-environment interactions and candidate genes.

Authors:  Todd L Edwards; Digna R Velez Edwards; Raquel Villegas; Sarah S Cohen; Maciej S Buchowski; Jay H Fowke; David Schlundt; Jirong Long; Ji Rong Long; Qiuyin Cai; Wei Zheng; Xiao-Ou Shu; Margaret K Hargreaves; Jeffrey Smith; Smith Jeffrey; Scott M Williams; Lisa B Signorello; William J Blot; Charles E Matthews
Journal:  Am J Epidemiol       Date:  2011-11-20       Impact factor: 4.897

4.  Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene.

Authors:  Lina E Aguirre; Georgia Colleluori; David Robbins; Richard Dorin; Vallabh O Shah; Rui Chen; Irum Zeb Jan; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal
Journal:  Endocrine       Date:  2019-07-19       Impact factor: 3.633

5.  Estrogen synthesis genes CYP19A1, HSD3B1, and HSD3B2 in hypertensive disorders of pregnancy.

Authors:  Masanori Shimodaira; Tomohiro Nakayama; Ichiro Sato; Naoyuki Sato; Noriko Izawa; Yoshihiro Mizutani; Kiyohide Furuya; Tatsuo Yamamoto
Journal:  Endocrine       Date:  2012-05-26       Impact factor: 3.633

6.  Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study.

Authors:  Stephanie D Boone; Kathy B Baumgartner; Richard N Baumgartner; Avonne E Connor; Christina M Pinkston; Shesh N Rai; Elizabeth C Riley; Lisa M Hines; Anna R Giuliano; Esther M John; Mariana C Stern; Gabriela Torres-Mejía; Roger K Wolff; Martha L Slattery
Journal:  Cancer Causes Control       Date:  2014-08-05       Impact factor: 2.506

7.  Association of aromatase and estrogen receptor gene polymorphisms with hip fractures.

Authors:  C Valero; J L Pérez-Castrillón; M T Zarrabeitia; J L Hernández; M A Alonso; J del Pino-Montes; J M Olmos; J González-Macías; J A Riancho
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

8.  Common coding variant in the TCF7L2 gene and study of the association with type 2 diabetes in Japanese subjects.

Authors:  Kiyoshi Kunika; Toshihito Tanahashi; Shusuke Numata; Shu-Ichi Ueno; Tetsuro Ohmori; Naoto Nakamura; Kazue Tsugawa; Katsuyuki Miyawaki; Maki Moritani; Hiroshi Inoue; Mitsuo Itakura
Journal:  J Hum Genet       Date:  2008-11-18       Impact factor: 3.172

9.  Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.

Authors:  Nicola Napoli; Antonella Rastelli; Cynthia Ma; Jayasree Yarramaneni; Swapna Vattikutti; Gerard Moskowitz; Tusar Giri; Cheryl Mueller; Vibhati Kulkarny; Clifford Qualls; Matthew Ellis; Reina Armamento-Villareal
Journal:  Bone       Date:  2013-05-01       Impact factor: 4.398

Review 10.  Genetics of osteoporosis: accelerating pace in gene identification and validation.

Authors:  Wen-Feng Li; Shu-Xun Hou; Bin Yu; Meng-Meng Li; Claude Férec; Jian-Min Chen
Journal:  Hum Genet       Date:  2009-12-12       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.